drugset

drugset / Trial / NCT00749632

A Study of Oxybutynin for the Treatment of Urge Urinary Incontinence

NCT00749632 ↗

Phase 2 Completed 45 enrolled FemmePharma Global Healthcare, Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety of three doses of oxybutynin for the treatment of urge urinary incontinence.

Timeline

Start: 2007-07
Primary completion: 2008-10
Completion: 2008-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Oxybutynin	Small molecule	—	Other

Indications